Commonwealth Equity Services’s Viking Therapeutics VKTX Stock Holding History

Commonwealth Equity Services’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93M	Sell	49,464 -1,825	-4%	-$59K	﹤0.01%	2144
2026 Q1	$1.67M	Buy	51,289 +1,053	+2%	+$33.8K	﹤0.01%	2170
2025 Q4	$1.77M	Sell	50,236 -7,565	-13%	-$268K	﹤0.01%	2090
2025 Q3	$1.52M	Sell	57,801 -1,608	-3%	-$48K	﹤0.01%	2247
2025 Q2	$1.57M	Sell	59,409 -4,327	-7%	-$114K	﹤0.01%	2188
2025 Q1	$1.54M	Sell	63,736 -7,457	-10%	-$236K	﹤0.01%	2116
2024 Q4	$2.87M	Buy	71,193 +15,244	+27%	+$869K	﹤0.01%	1617
2024 Q3	$3.54M	Buy	55,949 +14,277	+34%	+$838K	0.01%	1462
2024 Q2	$2.21M	Buy	41,672 +24,332	+140%	+$1.59M	﹤0.01%	1722
2024 Q1	$1.42M	Buy	+17,340	New	+$772K	﹤0.01%	2004
2020 Q2	–	Sell	-10,001	Closed	-$46K	–	3014
2020 Q1	$46K	Buy	+10,001	New	+$61.5K	﹤0.01%	2695
2019 Q3	–	Sell	-16,500	Closed	-$136K	–	2886
2019 Q2	$136K	Hold	16,500	–	–	﹤0.01%	2594
2019 Q1	$164K	Hold	16,500	–	–	﹤0.01%	2516
2018 Q4	$126K	Sell	16,500 -1,500	-8%	-$17.9K	﹤0.01%	2447
2018 Q3	$313K	Buy	+18,000	New	+$214K	﹤0.01%	2143

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Commonwealth Equity Services's VKTX Position: Q2 2026 in Review

Commonwealth Equity Services reduced its Viking Therapeutics (VKTX) stake by 3.6% in Q2 2026, selling an estimated $59K and leaving 49,464 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2144.

Commonwealth Equity Services first reported a position in VKTX in Q3 2018 and has held it in 15 quarters since. The position peaked at $3.54M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Commonwealth Equity Services held 49,464 shares of Viking Therapeutics worth $1.93M as of Q2 2026.
Commonwealth Equity Services sold 1,825 Viking Therapeutics shares in Q2 2026, an estimated $59K.
Viking Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #2144 holding.
Commonwealth Equity Services first reported a position in Viking Therapeutics in Q3 2018 and has held it in 15 quarters since.
Commonwealth Equity Services's Viking Therapeutics position peaked at $3.54M in Q3 2024.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.